LB Pharmaceuticals Stock Forward View - Triple Exponential Smoothing
| LBRX Stock | 23.92 -0.07 -0.29% |
The reference data on this page reflects Triple Exponential Smoothing output applied to LB Pharmaceuticals Common's historical daily closing prices. Forecast values and accuracy statistics are presented for informational purposes.
The Triple Exponential Smoothing forecasted value of LB Pharmaceuticals Common on the next trading day is expected to be 23.92 with a mean absolute deviation of 0.68 and the sum of the absolute errors of 40.16.As with simple exponential smoothing, in triple exponential smoothing models past LB Pharmaceuticals observations are given exponentially smaller weights as the observations get older. In other words, recent observations are given relatively more weight in forecasting than the older LB Pharmaceuticals Common observations. The forecast reference data presented here for LB Pharmaceuticals Common reflects Triple Exponential Smoothing model output and is intended as reference material for analytical use. Triple Exponential Smoothing Price Forecast For the 21st of March
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of LB Pharmaceuticals Common on the next trading day is expected to be 23.92 with a mean absolute deviation of 0.68 , mean absolute percentage error of 0.82 , and the sum of the absolute errors of 40.16 .Please note that although there have been many attempts to predict LBRX Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that LB Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest LB Pharmaceuticals | LB Pharmaceuticals Price Prediction | Research Analysis |
Forecasted Value
Forecasting LB Pharmaceuticals Common for the next session involves measuring the model's historical ability to define credible downside and upside scenarios. Used properly, these levels provide context around forecast dispersion rather than certainty about the next closing print.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of LB Pharmaceuticals stock data series using in forecasting. Note that when a statistical model is used to represent LB Pharmaceuticals stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.1109 |
| MAD | Mean absolute deviation | 0.6807 |
| MAPE | Mean absolute percentage error | 0.0301 |
| SAE | Sum of the absolute errors | 40.1607 |
Other Forecasting Options for LB Pharmaceuticals
Understanding LB Pharmaceuticals' price movement is a prerequisite for any investor considering LBRX as a position. LBRX Stock price charts are frequently cluttered with noise that can interfere with accurate interpretation.LB Pharmaceuticals Related Equities
The following equities are related to LB Pharmaceuticals within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing LB Pharmaceuticals against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
LB Pharmaceuticals Market Strength Events
For traders and investors in LB Pharmaceuticals Common, market strength indicators offer a quantitative framework for evaluating the stock's responsiveness to market conditions. These tools help identify when trading LB Pharmaceuticals shares is most likely to generate favorable returns.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 23.92 | |||
| Day Typical Price | 23.92 | |||
| Price Action Indicator | -0.04 | |||
| Period Momentum Indicator | -0.07 | |||
| Relative Strength Index | 50.48 |
LB Pharmaceuticals Risk Indicators
Analyzing LB Pharmaceuticals' risk indicators provides a critical input for price forecasting and investment risk management. By quantifying the risk in LB Pharmaceuticals' investment, investors can make more informed decisions about their exposure and hedging strategies.
| Mean Deviation | 3.04 | |||
| Semi Deviation | 3.77 | |||
| Standard Deviation | 4.18 | |||
| Variance | 17.46 | |||
| Downside Variance | 15.15 | |||
| Semi Variance | 14.21 | |||
| Expected Short fall | -3.30 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for LB Pharmaceuticals
Story coverage around LB Pharmaceuticals Common often expands when market conditions, narrative momentum, or risk-adjusted performance make the security more visible to investors. The practical risk is that faster visibility can increase both interest and skepticism at the same time.
Other Macroaxis Stories
Macroaxis publishes story content for a diverse readership that includes finance students, independent investors, money managers, and market-focused operating teams. What connects that audience is a focus on building stronger portfolios through better research, risk awareness, and comparative analysis.
Story Categories
Currently Trending Categories
LB Pharmaceuticals Short Properties
Short-interest signals around LB Pharmaceuticals Common can help investors judge whether skeptical positioning is starting to pressure price predictability and market tone. A disciplined short-interest review can make timing decisions more informed under rising skepticism.
| Common Stock Shares Outstanding | 3.5 M | |
| Cash And Short Term Investments | 28 M |